TNFRSF12A

Across TCGA pan-cancer cohorts, TNFRSF12A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TNFRSF12A data layer compared with 28 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TNFRSF12A mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TNFRSF12A expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where TNFRSF12A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.735	0.940	.001	54	view →
PDAC	DFS	Quartile	All	0.254	0.495	.003	45	view →
LUAD	DFS	Median	II,III,IV	0.719	0.935	.010	6	view →
LSCC	DFS	Median	All	0.615	0.790	.020	2	view →
HNSC	DFS	Quartile	All	0.884	0.695	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TNFRSF12A–CCRCC (OS)

Open the CCRCC breakdown →